BR100 Decreased By (-1.39%)
BR30 Decreased By (-1.72%)
KSE100 Decreased By (-1.3%)
KSE30 Decreased By (-1.25%)
AGHA 7.92 Decreased By ▼ -0.17 (-2.1%)
BECO 5.20 Decreased By ▼ -0.07 (-1.33%)
BML 59.25 Decreased By ▼ -0.13 (-0.22%)
BOP 33.68 Decreased By ▼ -0.51 (-1.49%)
CNERGY 9.81 Increased By ▲ 0.19 (1.98%)
CSIL 5.42 Decreased By ▼ -0.08 (-1.45%)
FCCL 53.52 Decreased By ▼ -0.63 (-1.16%)
FFL 16.68 Decreased By ▼ -0.16 (-0.95%)
FNEL 1.21 Decreased By ▼ -0.02 (-1.63%)
KEL 7.35 Decreased By ▼ -0.24 (-3.16%)
KOSM 5.61 Decreased By ▼ -0.07 (-1.23%)
LOTCHEM 29.11 Decreased By ▼ -1.32 (-4.34%)
MLCF 95.50 Decreased By ▼ -2.66 (-2.71%)
NBP 204.35 Decreased By ▼ -4.44 (-2.13%)
NCPL 58.24 Decreased By ▼ -1.37 (-2.3%)
NPL 67.79 Decreased By ▼ -2.08 (-2.98%)
OGDC 317.94 Decreased By ▼ -5.42 (-1.68%)
PACE 10.71 Decreased By ▼ -0.36 (-3.25%)
PAEL 41.83 Decreased By ▼ -0.42 (-0.99%)
PIBTL 16.50 Decreased By ▼ -0.32 (-1.9%)
PPL 219.74 Decreased By ▼ -4.99 (-2.22%)
PRL 44.59 Increased By ▲ 2.94 (7.06%)
PTC 70.77 Decreased By ▼ -0.35 (-0.49%)
SSGC 28.93 Decreased By ▼ -0.38 (-1.3%)
TBL 9.84 Decreased By ▼ -0.12 (-1.2%)
TELE 8.76 Decreased By ▼ -0.23 (-2.56%)
TPL 16.45 Decreased By ▼ -0.07 (-0.42%)
TPLP 12.10 Decreased By ▼ -0.67 (-5.25%)
TREET 22.80 Decreased By ▼ -0.26 (-1.13%)
TRG 60.03 Decreased By ▼ -0.42 (-0.69%)
Topic

US FDA

US FDA expected to authorize Pfizer vaccine for 12-15-year-olds soon

US FDA expected to authorize Pfizer vaccine for 12-15-year-olds soon

Published 05 May, 2021 06:26pm
  • The approval is highly anticipated after the drugmaker said in March the vaccine was found to be safe, effective and produced a robust antibody responses in 12- to 15-year-olds in a clinical trial.
  • The vaccine has already been cleared in the United States for those aged 16 and above.
Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Published 16 Apr, 2021 05:45pm
  • The request made to the US Food and Drug Administration is not due to any new safety issues, but in response to the new variants in the country that could be resistant to bamlanivimab when used alone, the drugmaker said in a statement.
  • Hospitals with bamlanivimab supply should now order etesevimab to pair with it, Lilly said.
Loading...